OLMA

SEC filing OLMA Reports Encouraging Phase 1 Data for OP-3136, KAT6 Inhibitor Shows Anti-Tumor Activity, Manageable Safety Profile

11d ago

News Olema Pharmaceuticals GAAP EPS of -$0.52 beats by $0.01

21d ago

SEC filing OLMA Reports $218.5M Offering Proceeds, $505.4M Cash, Palazestrant Phase 3 Data Fall 2026

78d ago

Scanner Unusual buy pressure (5.4x avg, 74% up-volume, +6.9% / +1.11 intraday, above VWAP)

84d ago

Insider trade Sale by Shawnte Mitchell (CHIEF LEGAL OFFICER)

88d ago

Insider trade Sale by David C. Myles

104d ago

Insider trade Sale by Shane William Charles Kovacs

104d ago

Insider trade Sale by Cyrus Harmon

104d ago

Insider trade Sale by Cyrus Harmon

104d ago

News LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA)

123d ago

News Olema Insider Sells $8 Million in Shares After 300% Stock Surge

144d ago

Failures to deliver 492,260 shares failed to deliver

150d ago

News Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

153d ago

Insider trade Sale by Zojwalla Naseem (Chief Medical Officer)

160d ago

Insider trade Sale by Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF)

160d ago

Insider trade Sale by CLARK IAN T

160d ago